Shineway Pharm (02877.HK) Sets 27 March 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal
Bulletin Express
Mar 17
China Shineway Pharmaceutical Group Limited announced that its Board of Directors will convene on 27 March 2026 at Suite 3109, 31/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong.
The agenda includes:
1. Approval for publication of the consolidated annual results for the financial year ended 31 December 2025.
2. Consideration of a dividend declaration for shareholders.
The notice was signed by Chairman Li Zhenjiang and dated 17 March 2026. The Board currently comprises three executive directors, one non-executive director, and three independent non-executive directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.